Tricida, Inc. (TCDA): Price and Financial Metrics
GET POWR RATINGS... FREE!
TCDA Stock Price Chart Interactive Chart >
TCDA Price/Volume Stats
| Current price | $8.81 | 52-week high | $9.90 |
| Prev. close | $9.00 | 52-week low | $3.55 |
| Day low | $8.71 | Volume | 161,700 |
| Day high | $9.14 | Avg. volume | 270,593 |
| 50-day MA | $8.18 | Dividend yield | N/A |
| 200-day MA | $5.39 | Market Cap | 444.45M |
Tricida, Inc. (TCDA) Company Bio
Tricida, Inc., a late-stage pharmaceutical company, focuses on developing therapeutics to address renal, metabolic, and cardiovascular disease. Its lead product candidate, TRC101, a non-absorbed orally-administered polymer drug that is in Phase III clinical trials used to treat metabolic acidosis in patients with chronic kidney disease. The company was founded in 2013 and is based in South San Francisco, California.
Latest TCDA News From Around the Web
Below are the latest news stories about Tricida Inc that investors may wish to consider to help them evaluate TCDA as an investment opportunity.
Tricida to Present at the 40th Annual J.P. Morgan Healthcare Conference and the H.C. Wainwright BIOCONNECT Virtual ConferenceSOUTH SAN FRANCISCO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA) today announced that it will present at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 at 7:30 am PT / 10:30 am ET. Gerrit Klaerner, Ph.D., Tricida’s Founder, President and CEO, will provide a company overview, business update and progress on the company’s key initiatives. The live presentation will be accessible on the Tricida website at IR.Tricida.com. An archive of the |
Tricida to Present at the 40th Annual J.P. Morgan Healthcare ConferenceSOUTH SAN FRANCISCO, Calif., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA) today announced that it will present at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 at 10:30 am PT / 1:30 pm ET. Gerrit Klaerner, Ph.D., Tricida’s Founder, President and CEO, will provide a company overview, business update and progress on the company’s key initiatives. A live webcast of the presentation will be accessible on the Tricida website at IR.Tricida.com. An ar |
Do Options Traders Know Something About Tricida (TCDA) Stock We Don't?Investors need to pay close attention to Tricida (TCDA) stock based on the movements in the options market lately. |
Why Tricida Stock Is Jumping TodayShares of Tricida (NASDAQ: TCDA) were jumping 11% higher as of 11:23 a.m. EST on Tuesday. The solid gain came after the company announced that it had entered into definitive agreements to sell stock and warrants that will generate gross proceeds of around $42 million. It's par for the course for drugmakers to raise additional capital through issuing new shares and/or warrants. |
Tricida Raises $42 Million in Registered Direct Equity FinancingSOUTH SAN FRANCISCO, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer, a non-absorbed, orally-administered polymer designed to slow chronic kidney disease (CKD) progression in patients with metabolic acidosis and CKD, announced today that it has entered into definitive agreements with certain investors for the purchase and sale of common stock, pre-fun |
TCDA Price Returns
| 1-mo | N/A |
| 3-mo | 91.94% |
| 6-mo | 115.40% |
| 1-year | 18.26% |
| 3-year | -58.23% |
| 5-year | N/A |
| YTD | -7.85% |
| 2021 | 35.60% |
| 2020 | -81.32% |
| 2019 | 60.05% |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...